MariTide

Synonymes : LY3305677, MARITIDE, GLP-1/GIP dual agonist, OXM-3 analog, Glucagon/GLP-1 receptor dual agonist

MariTide is a synthetic peptide engineered as a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, with additional activity at the glucagon receptor. This unique triple agonist profile is designed to leverage the complementary metabolic benefits of each receptor: GLP-1 for glycemic control and appetite suppression, GIP for insulin sensitization and adipose tissue regulation, and glucagon for energy expenditure and lipid metabolism. The peptide incorporates non-natural amino acids and a fatty acid side chain to extend its half-life, allowing for once-weekly dosing. Its molecular architecture is based on the oxyntomodulin (OXM) scaffold, modified for enhanced stability and receptor potency.

MariTide is produced via solid-phase peptide synthesis and purified by preparative HPLC to ensure high purity and consistent bioactivity. It is supplied as a lyophilized powder for reconstitution, suitable for preclinical and clinical research applications. The compound is manufactured under cGMP-like conditions, with rigorous quality control to meet the demands of pharmaceutical development.

In the competitive landscape of metabolic disease therapeutics, MariTide stands out for its balanced receptor activation and promising clinical profile. It is being investigated for the treatment of obesity, type 2 diabetes, and related metabolic disorders. Researchers value MariTide for its potential to deliver superior weight loss and glycemic benefits compared to single or dual agonists, making it a valuable tool for studying multi-receptor targeting strategies.

Structure chimique et propriétés

MariTide is a 39-amino acid peptide with a molecular weight of approximately 4600 Da. It features a modified backbone that includes α-aminoisobutyric acid (Aib) substitutions to enhance helical stability and resist enzymatic degradation. A C-16 fatty diacid moiety is conjugated via a linker to the lysine residue at position 20, promoting albumin binding and extending circulation time. The peptide is highly soluble in water and physiological buffers, and it adopts a predominantly α-helical conformation in solution, which is critical for receptor interaction.

Mécanisme d'action

• GLP-1 receptor activation: Stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways.
• GIP receptor activation: Enhances insulin sensitivity, promotes adipocyte differentiation and lipid storage, and may improve bone density.
• Glucagon receptor activation: Increases energy expenditure and lipolysis, contributing to weight loss and improved lipid profiles.
• Synergistic effect: The combined activation of these receptors leads to improved glycemic control and more effective weight reduction than single agonists.

Spécifications de qualité

Approvisionnement et documentation

• Capacité: Up to 100 grams per month
• Délai de livraison: 3 à 5 jours ouvrés (articles en stock)
• Documentation: COA, MSDS, TDS, HPLC chromatogram, mass spectrometry data
• Emballage: Lyophilized powder in sealed glass vials under argon

Demande de devis

• LyvBio Co. — E-mail : info@lyvbio.com